Bio-Pharm Solutions (B-PS) is a new drug developer specializing in the central nervous system (CNS) and rare diseases. It is a fast-growing company that aims to become a specialty pharmaceutical company in the global market. Bio-Pharm Solutions is developing new drugs that meet global standards and conducting global clinical trials approved by US FDA and EMA with the CEO, who have successfully developed several global new drugs, playing a central role from the stages of discovery to clinical trials.
Through joint research with the National Institutes of Health (NIH) and cooperation with consulting networks of global experts, the company obtained the Investigational New Drug (IND) approval from the US FDA IND for its first drug JBPOS0101, an epilepsy medicine, in 2013, within five years since its establishment and began to develop new drugs. This drug is currently undergoing infantile spasms phase 2 clinical trial and status epilepticus phase 1 clinical trial in the US, and epilepsy and Alzheimer’s Disease phase 2 clinical trial is in the wings.
In addition, the company has more than 10 new drug pipelines, including ADD422007 with a focus on diabetic neuropathic pain and ADD485002 with a focus on Parkinson’s Disease, and six drugs, including JBPOS0101, were listed in the ‘Red Book’ of the US National Institutes of Health (NIH) ESTP as drugs with high potential for being the best epilepsy medicine. As these pipelines show the possibility of developing medicines in various areas, including neuroprotection, depression, and cancer as well as LGS and Dravet syndrome in addition to the above indications, the company is pursuing a technology transfer (licensing deal) deal with global pharmaceutical companies.